Trials / Completed
CompletedNCT01233557
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- University of Aberdeen · Academic / Other
- Sex
- Male
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.
Conditions
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2010-11-03
- Last updated
- 2015-11-05
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01233557. Inclusion in this directory is not an endorsement.